DE69837094D1 - Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma - Google Patents

Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma

Info

Publication number: DE69837094D1
Authority: DE; Germany
Prior art keywords: host; antigen; preventing; immune; methods
Prior art date: 1997-09-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69837094T

Other languages

English (en)

Other versions

DE69837094T2 (de

Inventor

Eyal Raz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California

Original Assignee

University of California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-05

Filing date

1998-09-04

Publication date

2007-03-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25454211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69837094(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-09-04 Application filed by University of California filed Critical University of California

2007-03-29 Publication of DE69837094D1 publication Critical patent/DE69837094D1/de

2007-08-30 Application granted granted Critical

2007-08-30 Publication of DE69837094T2 publication Critical patent/DE69837094T2/de

2018-09-05 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
208000006673 asthma Diseases 0.000 title 1
239000000427 antigen Substances 0.000 abstract 3
102000036639 antigens Human genes 0.000 abstract 3
108091007433 antigens Proteins 0.000 abstract 3
238000000034 method Methods 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
230000003308 immunostimulating effect Effects 0.000 abstract 2
230000004043 responsiveness Effects 0.000 abstract 2
206010061218 Inflammation Diseases 0.000 abstract 1
210000003714 granulocyte Anatomy 0.000 abstract 1
230000003053 immunization Effects 0.000 abstract 1
238000002649 immunization Methods 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000001235 sensitizing effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants

DE69837094T 1997-09-05 1998-09-04 Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma Expired - Lifetime DE69837094T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US92712097A	1997-09-05	1997-09-05
US927120		1997-09-05
PCT/US1998/018382 WO1999011275A2 (en)	1997-09-05	1998-09-04	Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation

Publications (2)

Publication Number	Publication Date
DE69837094D1 true DE69837094D1 (de)	2007-03-29
DE69837094T2 DE69837094T2 (de)	2007-08-30

Family

ID=25454211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69837094T Expired - Lifetime DE69837094T2 (de)	1997-09-05	1998-09-04	Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma

Country Status (13)

Country	Link
US (3)	US6498148B1 (de)
EP (2)	EP1872786A1 (de)
JP (1)	JP4663113B2 (de)
AT (1)	ATE353657T1 (de)
AU (1)	AU757175B2 (de)
CA (1)	CA2302805A1 (de)
CY (1)	CY1106571T1 (de)
DE (1)	DE69837094T2 (de)
DK (1)	DK1009413T3 (de)
ES (1)	ES2283070T3 (de)
HK (1)	HK1029515A1 (de)
PT (1)	PT1009413E (de)
WO (1)	WO1999011275A2 (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US20030109469A1 (en) *	1993-08-26	2003-06-12	Carson Dennis A.	Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
JP4359654B2 (ja) *	1996-01-30	2009-11-04	ザリージェンツオブザユニバーシティーオブカリフォルニア	抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
US20030078223A1 (en) *	1996-01-30	2003-04-24	Eyal Raz	Compositions and methods for modulating an immune response
US6610661B1 (en) *	1996-10-11	2003-08-26	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
CA2268957C (en)	1996-10-25	2008-04-29	Minnesota Mining And Manufacturing Company	Immune response modifier compounds for treatment of th2 mediated and related diseases
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
JP4663113B2 (ja) *	1997-09-05	2011-03-30	ザリージェンツオブザユニバーシティオブカリフォルニア	抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
NZ508650A (en) *	1998-05-14	2003-05-30	Coley Pharm Gmbh	Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
DE69932717T2 (de)	1998-05-22	2007-08-09	Ottawa Health Research Institute, Ottawa	Methoden und produkte zur induzierung mukosaler immunität
WO2000020039A1 (en) *	1998-10-05	2000-04-13	The Regents Of The University Of California	Methods and adjuvants for stimulating mucosal immunity
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CN1330513A (zh) *	1999-04-06	2002-01-09	东卡罗来纳大学	低腺苷反义寡核苷酸、组合物、试剂盒及与支气管紧缩、肺炎、过敏及表面活性剂缺失相关的通气途径疾病的治疗方法
EP1176966B1 (de)	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
EP1204425B1 (de)	1999-08-19	2009-01-07	Dynavax Technologies Corporation	Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001047530A1 (en) *	1999-12-28	2001-07-05	Murdoch Childrens Research Institute	A method of therapy and prophylaxis of inflammation
EP1322655B1 (de) *	2000-01-14	2007-11-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
US6552006B2 (en)	2000-01-31	2003-04-22	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US7157437B2 (en) *	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) *	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020107212A1 (en) *	2000-03-10	2002-08-08	Nest Gary Van	Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en)	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) *	2000-03-10	2002-03-07	Nest Gary Van	Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
WO2001085910A2 (en) *	2000-05-05	2001-11-15	The Regents Of The University Of California	Agents that modulate dna-pk activity and methods of use thereof
JP2005503320A (ja) *	2000-08-25	2005-02-03	イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド	ＣｐＧ−含有ポリヌクレオチドで自己免疫疾患を処置または防止する方法
DE60142410D1 (de) *	2000-12-27	2010-07-29	Dynavax Tech Corp	Immunomodulatorische polynukleotide und verfahren zur deren verwendung
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
JP2004529091A (ja) *	2001-01-30	2004-09-24	アルタケム・ファーマ・リミテッド	免疫療法剤と共に使用するためのペリレンキノン
DE60235971D1 (de) *	2001-02-20	2010-05-27	Maruho Kk	Neue medizinische verwendung von alpha-antigen oder alpha-antigen-gen
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
CN100334228C (zh)	2001-06-21	2007-08-29	戴纳瓦克斯技术公司	嵌合免疫调制化合物及其使用方法
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003012061A2 (en) *	2001-08-01	2003-02-13	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
WO2003014316A2 (en)	2001-08-07	2003-02-20	Dynavax Technologies Corporation	Immunomodulatory compositions, formulations, and methods for use thereof
US7354909B2 (en)	2001-08-14	2008-04-08	The United States Of America As Represented By Secretary Of The Department Of Health And Human Services	Method for rapid generation of mature dendritic cells
SI1446162T1 (sl)	2001-08-17	2009-04-30	Coley Pharm Gmbh	Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljĹˇano aktivnostjo
EP2196217A1 (de)	2001-09-14	2010-06-16	Cytos Biotechnology AG	Verpackung von immunstimulierenden Mitteln in virusähnischen Partikeln: Herstellungsverfahren und Verwendung
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
DE10229872A1 (de) *	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
NZ538628A (en)	2002-08-12	2008-06-30	Dynavax Tech Corp	Immunomodulatory compositions, methods of making, and methods of use thereof
AR040996A1 (es) *	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US8263091B2 (en)	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
JP4976653B2 (ja)	2002-11-01	2012-07-18	ザガバメントオブザユナイテッドステイツオブアメリカアズリプレゼンティッドバイザセクレタリーオブザデパートメントオブヘルスアンドヒューマンサービシス	免疫刺激性ＣｐＧオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法
WO2004041183A2 (en) *	2002-11-01	2004-05-21	The Regents Of The University Of California	Methods of treating pulmonary fibrotic disorders
US20050124565A1 (en) *	2002-11-21	2005-06-09	Diener John L.	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) *	2002-11-21	2018-10-16	Archemix Llc	Aptamers comprising CPG motifs
US8853376B2 (en)	2002-11-21	2014-10-07	Archemix Llc	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8039443B2 (en) *	2002-11-21	2011-10-18	Archemix Corporation	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
AU2003300919A1 (en) *	2002-12-11	2004-06-30	Coley Pharmaceutical Gmbh	5' cpg nucleic acids and methods of use
CN100546998C (zh)	2002-12-23	2009-10-07	戴纳伐克斯技术股份有限公司	免疫刺激序列寡核苷酸和使用方法
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
JP2006516099A (ja)	2002-12-23	2006-06-22	ダイナバックステクノロジーズコーポレイション	分枝状の免疫調節化合物及び該化合物の使用方法
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
CA2517839A1 (en)	2003-03-26	2004-10-07	Martin F. Bachmann	Melan-a peptide analogue-virus-like-particle conjugates
US20040235770A1 (en) *	2003-04-02	2004-11-25	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
JP2007525177A (ja)	2003-04-21	2007-09-06	アーケミックスコーポレイション	血小板由来増殖因子に対する安定化アプタマーおよび腫瘍治療剤としてのそれらの使用
CA2557633A1 (en) *	2004-03-05	2005-09-22	Archemix Corp.	Aptamers to the human il-12 cytokine family and their use as autoimmune disease therapeutics
US20060193821A1 (en) *	2004-03-05	2006-08-31	Diener John L	Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
US7579450B2 (en) *	2004-04-26	2009-08-25	Archemix Corp.	Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP1766094A4 (de)	2004-05-18	2009-11-25	Vical Inc	Grippevirusimpfstoffzusammensetzung und verwendungsverfahren
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
MY159370A (en)	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
EP3034089A1 (de)	2004-11-02	2016-06-22	Archemix LLC	Stabilisierte aptamere für einen aus plättchen gewonnenen wachstumsfaktor und deren verwendung als onkologietherapeutika
NZ561144A (en) *	2005-03-04	2009-09-25	Dynavax Tech Corp	Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1874325A2 (de) *	2005-04-08	2008-01-09	Coley Pharmaceutical Group, Inc.	Verfahren zur behandlung von durch infektionserkrankungen verschlimmertes asthma
US8101385B2 (en)	2005-06-30	2012-01-24	Archemix Corp.	Materials and methods for the generation of transcripts comprising modified nucleotides
MX2007016561A (es)	2005-06-30	2008-03-10	Archemix Corp	Materiales y metodos para la generacion de transcriptos de acido nucleico completamente modificados en la posicion 2.
WO2007016762A1 (en)	2005-08-10	2007-02-15	Quest Pharmatech Inc.	Perylenequinone derivatives and uses thereof
AU2006325225B2 (en)	2005-12-14	2013-07-04	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
CA2653939C (en)	2006-05-31	2013-01-22	Toray Industries, Inc.	Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
CA2655108C (en)	2006-06-12	2019-05-07	Cytos Biotechnology Ag	Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
US8454991B2 (en) *	2006-07-24	2013-06-04	Quest Pharmatech Inc.	Method and device for photodynamic therapy
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
AU2007280690C1 (en)	2006-07-31	2012-08-23	Curevac Gmbh	Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
CA2669137A1 (en)	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
RU2545701C2 (ru)	2008-01-31	2015-04-10	Куревак Гмбх	НУКЛЕИНОВЫЕ КИСЛОТЫ ФОРМУЛЫ (I) (NuGlXmGnNv)a И ИХ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИММУННОСТИМУЛИРУЮЩИХ АГЕНТОВ/АДЪЮВАНТОВ
BRPI0910036B8 (pt) *	2008-03-25	2021-05-25	Juvaris Biotherapeutics Inc	kit compreendendo um primeiro administrador para via intra-venosa de um complexo de lipídio catiônico-dna (cldc) e um segundo administrador de uma vacina
AU2009246169B2 (en)	2008-05-15	2015-01-22	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US8598327B2 (en)	2009-08-18	2013-12-03	Baxter International Inc.	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
AU2010284329B2 (en) *	2009-08-18	2015-04-16	Takeda Pharmaceutical Company Limited	Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
JP2013521002A (ja)	2010-03-05	2013-06-10	プレジデントアンドフェロウズオブハーバードカレッジ	誘導樹状細胞組成物及びその使用
DK2449113T3 (en)	2010-07-30	2016-01-11	Curevac Ag	Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation
JP6002691B2 (ja)	2011-02-11	2016-10-05	バクスアルタゲーエムベーハー	組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
CA2902560A1 (en)	2013-03-14	2014-09-25	President And Fellows Of Harvard College	Nanoparticle-based compositions
MX369469B (es)	2013-08-21	2019-11-08	Curevac Ag	Vacuna contra el virus respiratorio sincitial.
CA2936286A1 (en)	2014-04-01	2015-10-08	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
KR20180014009A (ko)	2015-05-29	2018-02-07	머크 샤프 앤드 돔 코포레이션	암을 치료하기 위한 pd-1 길항제 및 cpg-c 유형 올리고뉴클레오티드의 조합
CN111840309A (zh) *	2020-08-19	2020-10-30	四川大学华西医院	鸟嘌呤核苷的新用途
WO2023081486A1 (en)	2021-11-08	2023-05-11	Nurix Therapeutics, Inc.	Toll-like receptor therapy combinations with cbl-b inhibitor compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1234718A (en)	1914-03-21	1917-07-31	Int Harvester Canada	Buckle.
US3596660A (en) *	1969-05-12	1971-08-03	Illinois Tool Works	Injection device
US3725545A (en)	1971-02-03	1973-04-03	R Maes	Enhancement of antibody production by nucleic acid-polycation complexes
US3906092A (en)	1971-11-26	1975-09-16	Merck & Co Inc	Stimulation of antibody response
US5276019A (en)	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5268365A (en)	1988-03-11	1993-12-07	Rudolph Frederick B	Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance
US5750666A (en) *	1988-05-26	1998-05-12	Competitve Technologies, Inc.	Polynucleotide phosphorodithioate compounds
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
AU705889B2 (en)	1993-08-26	1999-06-03	Regents Of The University Of California, The	Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
ES2267100T5 (es)	1994-07-15	2011-04-08	The University Of Iowa Research Foundation	Oligonucleótidos inmunomoduladores.
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US5972693A (en) *	1995-10-24	1999-10-26	Curagen Corporation	Apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
JP4359654B2 (ja) *	1996-01-30	2009-11-04	ザリージェンツオブザユニバーシティーオブカリフォルニア	抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
US6610661B1 (en) *	1996-10-11	2003-08-26	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (de)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
AU738513B2 (en) *	1997-02-28	2001-09-20	University Of Iowa Research Foundation, The	Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
EP0983289A4 (de)	1997-05-19	2001-04-25	Merck & Co Inc	Oligonukleotidhilfsmittel
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE432348T1 (de) *	1997-06-06	2009-06-15	Univ California	Inhibitoren von immunstimulatorischen dna sequenz aktivität
JP4663113B2 (ja) *	1997-09-05	2011-03-30	ザリージェンツオブザユニバーシティオブカリフォルニア	抗原刺激顆粒球媒介炎症を予防または軽減するための免疫刺激オリゴヌクレオチドの使用
US20030103938A1 (en) *	2001-05-09	2003-06-05	Alk-Abello A/S	Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US8946387B2 (en) *	2002-08-14	2015-02-03	Macrogenics, Inc.	FcγRIIB specific antibodies and methods of use thereof
EP2901856B1 (de) *	2004-06-15	2017-08-09	Idera Pharmaceuticals, Inc.	Immunstimulatorische Oligonukleotidmultimere
CN101160401A (zh) *	2005-02-24	2008-04-09	科勒制药集团公司	免疫刺激寡核苷酸
EP2021013A2 (de) *	2006-04-18	2009-02-11	The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin	Tracheal-cytotoxin (tct) und verwandte verbindungen zur unterdrückung von immunantworten

1998
- 1998-09-04 JP JP2000508377A patent/JP4663113B2/ja not_active Expired - Lifetime
- 1998-09-04 DE DE69837094T patent/DE69837094T2/de not_active Expired - Lifetime
- 1998-09-04 EP EP07001453A patent/EP1872786A1/de not_active Withdrawn
- 1998-09-04 DK DK98945877T patent/DK1009413T3/da active
- 1998-09-04 ES ES98945877T patent/ES2283070T3/es not_active Expired - Lifetime
- 1998-09-04 CA CA002302805A patent/CA2302805A1/en not_active Abandoned
- 1998-09-04 PT PT98945877T patent/PT1009413E/pt unknown
- 1998-09-04 AT AT98945877T patent/ATE353657T1/de active
- 1998-09-04 WO PCT/US1998/018382 patent/WO1999011275A2/en active IP Right Grant
- 1998-09-04 EP EP98945877A patent/EP1009413B1/de not_active Revoked
- 1998-09-04 AU AU93023/98A patent/AU757175B2/en not_active Expired
1999
- 1999-01-21 US US09/235,742 patent/US6498148B1/en not_active Expired - Lifetime
2000
- 2000-12-02 HK HK00107748A patent/HK1029515A1/xx not_active IP Right Cessation
2002
- 2002-08-26 US US10/229,208 patent/US20030092663A1/en not_active Abandoned
2007
- 2007-05-09 CY CY20071100623T patent/CY1106571T1/el unknown
- 2007-08-06 US US11/834,206 patent/US20090131347A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030092663A1 (en)	2003-05-15
JP2002500159A (ja)	2002-01-08
US20090131347A1 (en)	2009-05-21
EP1872786A1 (de)	2008-01-02
WO1999011275A2 (en)	1999-03-11
AU757175B2 (en)	2003-02-06
PT1009413E (pt)	2007-05-31
DE69837094T2 (de)	2007-08-30
DK1009413T3 (da)	2007-06-11
WO1999011275A3 (en)	1999-06-03
CY1106571T1 (el)	2012-01-25
CA2302805A1 (en)	1999-03-11
US6498148B1 (en)	2002-12-24
ES2283070T3 (es)	2007-10-16
ATE353657T1 (de)	2007-03-15
EP1009413A2 (de)	2000-06-21
HK1029515A1 (en)	2001-04-06
EP1009413B1 (de)	2007-02-14
WO1999011275A9 (en)	1999-07-08
AU9302398A (en)	1999-03-22
JP4663113B2 (ja)	2011-03-30

Legal Events

Date	Code	Title	Description
2008-01-31	8363	Opposition against the patent

Publication	Publication Date	Title
DE69837094D1 (de)	2007-03-29	Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
ATE163195T1 (de)	1998-02-15	Lösliche liganden für cd40
DE69733145D1 (de)	2005-06-02	Verfahren zur behandlung von allergischen lungenkrankheiten
TR199902124T2 (xx)	2000-06-21	�ltihapl� hastal�klar�n tedavisinde yararl� k��k molek�ller.
TR200002731T2 (tr)	2001-04-20	Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
TR199902803T2 (xx)	2000-07-21	VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
ATE296839T1 (de)	2005-06-15	Antikörper zur krebsbehandlung und -diagnose
ATE190496T1 (de)	2000-04-15	Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
NO993847D0 (no)	1999-08-10	Fremgangsmåter og sammensetninger for behandling av allergisk astma og andre sykdommer som anvender deskarboetoksyloratadin
DK0380230T3 (da)	1995-01-16	Immunogene sammensætninger mod gastrin-peptider
ATE258796T1 (de)	2004-02-15	Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69635305D1 (de)	2006-03-02	Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
ATE281841T1 (de)	2004-11-15	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE359814T1 (de)	2007-05-15	Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
WO2003040725A3 (en)	2003-12-04	Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen
DE29504054U1 (de)	1996-07-25	Therapiegerät zur spezifischen funktionellen Elektromyostimulation glatter Muskelzellen
ATE148694T1 (de)	1997-02-15	Verfahren zur herstellung von 3(5)- methylpyrazolen
DK0542895T3 (da)	1997-05-12	Krydsreaktiv influenza A immunisering
EP0321094A3 (de)	1990-03-07	Behandlung von Faktor-VIII-Inhibitoren
RU95105747A (ru)	1997-06-10	Способ лечения алкогольной зависимости и антиалкогольная композиция
SI0804236T1 (en)	2003-08-31	Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
RU95118494A (ru)	1997-10-10	Способ лечения летней формы псориаза
DE69807208D1 (de)	2002-09-19	Verfahren zur behandlung von dicotylensamen um eine endospermfraktion zu erhalten
RU93037460A (ru)	1996-03-20	Способ лечения псориаза и пузырчатки